Delving into the Latest Updates on DP-4088 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

DP 4088, DPOC-4088

Target

thrombin

Mechanism

thrombin inhibitors(Factor IIa inhibitors)

Therapeutic Areas

Cardiovascular DiseasesHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Atrial FibrillationBlood Coagulation DisordersVenous Thrombosis

Originator Organization

Merck & Co., Inc.

Active Organization-

Inactive Organization

Diakron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Orchid Pharma Ltd.

+ [1]

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Structure

Molecular FormulaC19H16ClF3N6O2

InChIKeyAATHXZYXWMKUFC-UHFFFAOYSA-N

CAS Registry312904-62-4

A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters. Furthermore the relation between the blood concentrations and the blood clotting effect will be investigated. Safety will be investigated as well. The objective of these investigations is to determine the optimal dose of DPOC-4088 that, achieves a relevant increase in a specific blood clotting parameter (the ecarin clotting time) without safety concerns.

Start Date01 Feb 2012

Sponsor / Collaborator

Diakron Pharmaceuticals, Inc.

[+1]

NCT01347203 / CompletedPhase 1

A Randomized, Open-label, 4-period Crossover Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD) and the PK/PD Relationship of DPOC-4088 After Single Oral Dosing of 100 and 200 mg in 2 Prolonged Release Formulations (16 and 20 hr) in 12 Healthy Young Male Subjects

This will be a study existing of 4 periods, to evaluate for a single dose of 4 different tablets of DPOC-4088 the absorption and elimination from the body and the potential effect on blood clotting. The differences between the tablets are the dose (100 or 200 mg) and the rate of release of DPOC-4088 from the tablet (16 or 20 hours). The allocation of the tablets in each period will be determined by chance but is known upfront.

Start Date01 Apr 2011

Sponsor / Collaborator

Diakron Pharmaceuticals, Inc.

100 Clinical Results associated with DP-4088

Login to view more data

100 Translational Medicine associated with DP-4088

Login to view more data

100 Patents (Medical) associated with DP-4088

Login to view more data

100 Deals associated with DP-4088

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atrial Fibrillation	Phase 1	BE	Diakron Pharmaceuticals, Inc.	01 Feb 2012
Venous Thrombosis	Phase 1	US	Diakron Pharmaceuticals, Inc.	13 Aug 2008
Venous Thrombosis	Phase 1	IN	Orchid Pharma Ltd.	13 Aug 2008
Blood Coagulation Disorders	Phase 1	BE	Diakron Pharmaceuticals, Inc.	-
Blood Coagulation Disorders	Phase 1	-	Orchid Website Design Ltd.	-
Blood Coagulation Disorders	Phase 1	-	Merck Sharp & Dohme Corp.	-